Skip to content

Study · Non-randomized trial · n = 93 · 2011

4 results

Role of gonadotropin-releasing hormone antagonist in the management of subfertile couples with intrauterine insemination and controlled ovarian stimulation.

Bakas P, Konidaris S, Liapis A, Gregoriou O, Tzanakaki D, Creatsas G

Fertility and sterility19 Feb 2011Cited by 15 (Europe PMC)

PMID21334613 (opens in a new tab)DOI10.1016/j.fertnstert.2011.01.167 (opens in a new tab)PepBankPUB-21334613
Source linkPubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In patients with infertility, adding ganirelix increased clinical pregnancy rates compared with FSH alone.

    In plain wordsIn patients with infertility, adding ganirelix increased clinical pregnancy rates compared with FSH alone.

    Peptide
    Ganirelix
    Outcome
    IncreaseClinical pregnancy rate
    Study

    n = 93

    Comparator
    Recombinant FSH alone
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    0.25 mg/dAs given in this study (human).

    Measurements

    Clinical pregnancy rate
    22%
    ganirelix
    Clinical pregnancy rate
    11%
    control

    Source sentences

    Summary
    Clinical pregnancy rate (22% vs. 11%), cumulative pregnancy rate (52% vs. 31%), and number of mature follicles (2.1±1.08 vs. 1.4±0.95) were statistically significantly higher in the ganirelix group compared with the control group.
    4 context sentences
    Summary · context
    Prospective, controlled study.
    Summary · context
    Ninety-three patients with primary or secondary infertility.
    Summary · context
    Patients were allocated to controlled ovarian stimulation with recombinant FSH (50-150 IU/d) only (control group, n=45) or to recombinant FSH (50-150 IU/d) plus ganirelix (0.25 mg/d, starting when the leading follicle was ≥16 mm; n=48).
    Summary · context
    A single insemination was performed 36 hours after hCG was given (10,000 IU, IM) in both groups.
  2. 02HumanNon-randomized trialEfficacy outcome

    In patients with infertility, adding ganirelix increased cumulative pregnancy rates compared with FSH alone.

    In plain wordsIn patients with infertility, adding ganirelix increased cumulative pregnancy rates compared with FSH alone.

    Peptide
    Ganirelix
    Outcome
    IncreaseCumulative pregnancy rate
    Study

    n = 93

    Comparator
    Recombinant FSH alone
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    0.25 mg/dAs given in this study (human).

    Measurements

    Cumulative pregnancy rate
    52%
    ganirelix
    Cumulative pregnancy rate
    31%
    control

    Source sentences

    Summary
    Clinical pregnancy rate (22% vs. 11%), cumulative pregnancy rate (52% vs. 31%), and number of mature follicles (2.1±1.08 vs. 1.4±0.95) were statistically significantly higher in the ganirelix group compared with the control group.
    4 context sentences
    Summary · context
    Prospective, controlled study.
    Summary · context
    Ninety-three patients with primary or secondary infertility.
    Summary · context
    Patients were allocated to controlled ovarian stimulation with recombinant FSH (50-150 IU/d) only (control group, n=45) or to recombinant FSH (50-150 IU/d) plus ganirelix (0.25 mg/d, starting when the leading follicle was ≥16 mm; n=48).
    Summary · context
    A single insemination was performed 36 hours after hCG was given (10,000 IU, IM) in both groups.
  3. 03HumanNon-randomized trialEfficacy outcome

    In patients with infertility, adding ganirelix increased mature follicle numbers compared with FSH alone.

    In plain wordsIn patients with infertility, adding ganirelix increased mature follicle numbers compared with FSH alone.

    Peptide
    Ganirelix
    Outcome
    IncreaseMature follicle number
    Study

    n = 93

    Comparator
    Recombinant FSH alone
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    0.25 mg/dAs given in this study (human).

    Measurements

    Mature follicles
    2.1 follicles
    ganirelix mean
    Mature follicles variability
    1.08 follicles
    ganirelix reported plus/minus
    Mature follicles
    1.4 follicles
    control mean
    Mature follicles variability
    0.95 follicles
    control reported plus/minus

    Source sentences

    Summary
    Clinical pregnancy rate (22% vs. 11%), cumulative pregnancy rate (52% vs. 31%), and number of mature follicles (2.1±1.08 vs. 1.4±0.95) were statistically significantly higher in the ganirelix group compared with the control group.
    4 context sentences
    Summary · context
    Prospective, controlled study.
    Summary · context
    Ninety-three patients with primary or secondary infertility.
    Summary · context
    Patients were allocated to controlled ovarian stimulation with recombinant FSH (50-150 IU/d) only (control group, n=45) or to recombinant FSH (50-150 IU/d) plus ganirelix (0.25 mg/d, starting when the leading follicle was ≥16 mm; n=48).
    Summary · context
    A single insemination was performed 36 hours after hCG was given (10,000 IU, IM) in both groups.
  4. 04HumanNon-randomized trialEfficacy outcome

    In patients with infertility, adding ganirelix reduced premature luteinization compared with FSH alone.

    In plain wordsIn patients with infertility, adding ganirelix reduced premature luteinization compared with FSH alone.

    Peptide
    Ganirelix
    Outcome
    DecreasePremature luteinization rate
    Study

    n = 93

    Comparator
    Recombinant FSH alone
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    0.25 mg/dAs given in this study (human).

    Measurements

    Premature luteinization rate
    1.7%
    ganirelix
    Premature luteinization rate
    17.5%
    control

    Source sentences

    Summary
    The premature luteinization rate was significantly lower in the ganirelix group (1.7% vs. 17.5%).
    4 context sentences
    Summary · context
    Prospective, controlled study.
    Summary · context
    Ninety-three patients with primary or secondary infertility.
    Summary · context
    Patients were allocated to controlled ovarian stimulation with recombinant FSH (50-150 IU/d) only (control group, n=45) or to recombinant FSH (50-150 IU/d) plus ganirelix (0.25 mg/d, starting when the leading follicle was ≥16 mm; n=48).
    Summary · context
    A single insemination was performed 36 hours after hCG was given (10,000 IU, IM) in both groups.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.